NASDAQ:VVUS - VIVUS Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.65 -0.04 (-1.08 %)
(As of 04/18/2019 02:23 PM ET)
Previous Close$3.69
Today's Range$3.64 - $3.77
52-Week Range$2.15 - $9.90
Volume81,603 shs
Average Volume140,139 shs
Market Capitalization$38.83 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21
VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, and nonalcoholic steatohepatitis; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; Alvogen Malta Operations (ROW) Ltd; and Janssen Pharmaceuticals, Inc. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:VVUS
CUSIP92855110
Phone650-934-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$65.06 million
Book Value($3.77) per share

Profitability

Net Income$-36,950,000.00

Miscellaneous

Employees57
Market Cap$38.83 million
Next Earnings Date4/30/2019 (Confirmed)
OptionableOptionable

VIVUS (NASDAQ:VVUS) Frequently Asked Questions

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

When did VIVUS's stock split? How did VIVUS's stock split work?

VIVUS shares reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) released its quarterly earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.11. The biopharmaceutical company earned $20.11 million during the quarter. View VIVUS's Earnings History.

When is VIVUS's next earnings date?

VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, April 30th 2019. View Earnings Estimates for VIVUS.

Has VIVUS been receiving favorable news coverage?

Media headlines about VVUS stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. VIVUS earned a coverage optimism score of 0.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the company's share price in the next several days.

Who are some of VIVUS's key competitors?

What other stocks do shareholders of VIVUS own?

Who are VIVUS's key executives?

VIVUS's management team includes the folowing people:
  • Mr. Mark K. Oki, Sr. VP, CFO & Chief Accounting Officer (Age 50)
  • Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 54)
  • Dr. Santosh T. Varghese, Chief Medical Officer (Age 49)
  • Mr. John P. Amos, CEO & Director (Age 51)
  • Mr. Ken Suh, Pres

How do I buy shares of VIVUS?

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VIVUS's stock price today?

One share of VVUS stock can currently be purchased for approximately $3.65.

How big of a company is VIVUS?

VIVUS has a market capitalization of $38.83 million and generates $65.06 million in revenue each year. The biopharmaceutical company earns $-36,950,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. VIVUS employs 57 workers across the globe.

What is VIVUS's official website?

The official website for VIVUS is http://www.vivus.com.

How can I contact VIVUS?

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]


MarketBeat Community Rating for VIVUS (NASDAQ VVUS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  377 (Vote Underperform)
Total Votes:  689
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel